Analysts Set Alto Neuroscience, Inc. (NYSE:ANRO) Target Price at $19.00

Shares of Alto Neuroscience, Inc. (NYSE:ANRO) have received an average recommendation of “Moderate Buy” from the seven ratings firms that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and five have assigned a buy recommendation to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $19.00.

Several analysts have recently commented on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Alto Neuroscience in a research report on Wednesday, October 8th. HC Wainwright boosted their target price on Alto Neuroscience from $10.00 to $50.00 and gave the stock a “buy” rating in a research note on Friday, October 24th. Chardan Capital initiated coverage on shares of Alto Neuroscience in a research note on Monday, September 29th. They set a “buy” rating and a $15.00 price target for the company. Finally, Robert W. Baird upped their price objective on shares of Alto Neuroscience from $10.00 to $16.00 and gave the company an “outperform” rating in a report on Monday, October 20th.

Hedge Funds Weigh In On Alto Neuroscience

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ANRO. Vanguard Personalized Indexing Management LLC raised its position in shares of Alto Neuroscience by 13.7% during the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 17,045 shares of the company’s stock valued at $69,000 after buying an additional 2,055 shares in the last quarter. Citizens Financial Group Inc. RI increased its stake in shares of Alto Neuroscience by 19.0% during the third quarter. Citizens Financial Group Inc. RI now owns 40,000 shares of the company’s stock valued at $161,000 after buying an additional 6,394 shares during the period. AlphaCore Capital LLC lifted its holdings in Alto Neuroscience by 100.0% in the second quarter. AlphaCore Capital LLC now owns 20,000 shares of the company’s stock worth $44,000 after buying an additional 10,000 shares during the period. Bank of Montreal Can purchased a new stake in Alto Neuroscience in the second quarter worth about $25,000. Finally, Ground Swell Capital LLC purchased a new stake in Alto Neuroscience in the second quarter worth about $27,000.

Alto Neuroscience Stock Up 0.7%

NYSE:ANRO opened at $11.31 on Friday. The company has a market cap of $306.27 million, a PE ratio of -4.73 and a beta of 2.90. The firm’s 50 day simple moving average is $6.50 and its 200 day simple moving average is $4.04. The company has a debt-to-equity ratio of 0.18, a current ratio of 18.43 and a quick ratio of 18.43. Alto Neuroscience has a one year low of $1.60 and a one year high of $15.18.

Alto Neuroscience (NYSE:ANRO) last issued its quarterly earnings results on Wednesday, August 13th. The company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.57) by ($0.08). On average, research analysts anticipate that Alto Neuroscience will post -2.54 earnings per share for the current year.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.